Gitnux/Report 2026

Addiction Treatment Industry Statistics

With rates and outcomes shifting in 2025 and 2026, these addiction treatment industry statistics reveal what changed and what did not, right down to access, cost pressures, and treatment completion. Read to see the tension between higher demand and real world capacity, and the numbers behind where recovery systems are gaining ground and where they are still falling short.
263Statistics
70Sources
12Sections
1Visuals
45mRead
November 10, 2026Updated
Addiction Treatment Industry Statistics
Kevin O'BrienWritten by Kevin O'Brien·Edited by Isabelle Moreau·Fact-checked by Nicholas Chambers
Published ·Updated
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The addiction treatment industry at a glance

The U.S. addiction treatment industry served 7.6 million people in 2025, while 47.2 million people needed treatment, highlighting substantial unmet demand despite a large national provider base.

7.6M[3]
Received treatment in 2025
47.2M[3]
Needed treatment in 2025
15,472[3]
Treatment facilities in 2025
2.1M[3]
Received opioid-use medication in 2025
Market share & regions
The 2025 N-SUMHSS counted 15,472 substance-use treatment facilities across the United States and territories. Private for-profit providers accounted for 6,441 facilities, or approximately 41.6% of the total, while the detailed table also identifies private nonprofit and public operators.[3]
Segmentation
Outpatient care was the largest service segment in 2025, with 13,007 facilities offering some outpatient treatment, including 12,020 regular outpatient facilities and 6,540 intensive outpatient facilities. Residential treatment was offered by 3,424 facilities, while 1,163 facilities offered hospital inpatient care.[3]
Key players & concentration
The market is highly fragmented by facility count: the 2025 N-SUMHSS identified 15,472 facilities, including 6,441 private for-profit facilities and 4,740 private nonprofit facilities. The federal facility survey does not publish a national revenue-based concentration ratio for commercial operators.[3]
Pricing
For calendar year 2026, CMS set national Medicare payment rates for opioid-treatment-program bundles at $277.29 per weekly methadone bundle, $296.57 per weekly oral-buprenorphine bundle, and $2,063.77 per monthly injectable-buprenorphine bundle. These are national rates before locality adjustments and are not retail prices for all addiction-treatment services.[60]
Trends, drivers & challenges
Demand remains far above treatment capacity: 47.2 million people aged 12 or older needed substance-use treatment in 2025, but only 7.6 million received it. Telehealth reached 3.6 million people, while medication for opioid-use disorder reached 2.1 million, indicating continued movement toward medication-based and remote care alongside persistent access gaps.[3]
Consumer behavior & competition
In 2025, 2.6% of people aged 12 or older received substance-use treatment, equivalent to 7.6 million people, while only 16.0% of those classified as needing treatment received it. Outpatient treatment reached 4.4 million people, compared with 2.2 million receiving inpatient treatment, showing the predominance of less intensive care settings.[3]
M&A
Provider consolidation continued in 2026: Northpoint Recovery announced its acquisition of Brick House Recovery on November 9, 2026, adding three adult outpatient facilities and a virtual-treatment program to its network. The transaction illustrates ongoing expansion through multi-site outpatient and digital-care platforms, although deal value was not disclosed.[22]
Regulation
CMS regulates Medicare payment for opioid-treatment programs through HCPCS bundled-service codes and annual national and locality-adjusted rates. The 2026 national rates include weekly methadone, oral-buprenorphine, and non-drug treatment bundles, with the non-drug component updated using the Medicare Economic Index.[60]
Latest news
The latest federal demand data, released in 2026 from the 2025 NSDUH, reported 7.6 million people receiving substance-use treatment and 47.2 million needing it. Separately, CDC provisional data projected 67,798 drug-overdose deaths for the 12 months ending March 2026, keeping overdose prevention and treatment access central to industry demand.[3][61]

02 Ranking

Top 9 Companies in the Addiction Treatment Industry

The leading companies in the addiction treatment industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Camurus leads Gitnux's 2026 addiction treatment ranking with an Overall score of 9.1, with licenses Brixadi, long-acting buprenorphine treatment. Universal Health Services is the highest-ranked care provider at 9.0, with 346 inpatient behavioral health facilities and 168 outpatient facilities in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in long-acting buprenorphine

    Camurus

    SE

    Ranked #1 · 9.1 · Long-acting buprenorphine

    Why we picked it: Long-acting opioid-dependence medicines via Buvidal and licensed Brixadi address medication-based capacity constraints.

    See in ranking ↓Visit camurus.com ↗

  2. Leader in behavioral treatment provider

    Universal Health Services

    US

    Ranked #2 · 9.0 · Behavioral treatment provider

    Why we picked it: Facility footprint across inpatient and outpatient settings fits the industry’s outpatient-dominant service mix.

    See in ranking ↓Visit uhs.com ↗

  3. Leader in medication-assisted provider

    BayMark Health Services

    US

    Ranked #4 · 8.3 · Medication-assisted provider

    Why we picked it: Medication-assisted treatment aligns with 2.1M receiving opioid-use medication in 2025.

    See in ranking ↓Visit baymark.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 9 companies in the addiction treatment industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Camurus

Long-acting buprenorphine · SE

9.1
2

Universal Health Services

Behavioral treatment provider · US

9.0
3

Acadia Healthcare

Behavioral treatment provider · US

8.5
4

BayMark Health Services

Medication-assisted provider · US

8.3
5

Behavioral Health Group

Outpatient opioid clinics · US

8.3
6

Alkermes

VIVITROL medication for alcohol and opioid dependence · IE

8.3
7

Discovery Behavioral Health

Substance-use and behavioral treatment programs, US · US

8.0
8

Summit BHC

Residential and outpatient addiction treatment, US · US

7.5
9

American Addiction Centers

Residential and outpatient addiction treatment, US · US

7.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Kevin O'Brien. (2026, February 13). Top 9 companies in the addiction treatment industry. In Addiction Treatment Industry Statistics. Gitnux. https://gitnux.org/addiction-treatment-industry-statistics/#top-companies

report visual · Projection

U.S. substance use treatment discharge episodes

U.S. substance use treatment discharge episodes fell from 1.4M in 2020 to 1.3M in 2024.

1.4M count
Start
-2.84%
CAGR · 4y
1.3M count
Projected
20202024
source-verifiedsamhsa.gov2024

04 Statistics

Technology & Innovation

Psychiatrists show mixed AI readiness in 2026: 12% used AI for administrative tasks, while 86% supported evidence-based standards for AI mental-health applications. Behavioral-health facilities also show payer and telehealth adoption signals.

AI in the addiction treatment industry

  • 80% of surveyed psychiatrists were very or moderately concerned that mental-health professionals lacked adequate AI training in 2026 in the United States and Canada.[1]
  • 38% of surveyed psychiatrists said AI would make professionals more effective in 2026 in the United States and Canada.[1]
  • 40% of surveyed psychiatrists said AI-assisted treatment was riskier than traditional strategies in 2026 in the United States and Canada.[1]
  • 40% of surveyed psychiatrists had not used AI in their practice in 2026 in the United States and Canada.[1]
  • 12% of surveyed psychiatrists used AI for administrative tasks in 2026 in the United States and Canada.[1]
  • 86% of surveyed psychiatrists supported evidence-based standards for AI mental-health applications in 2026 in the United States and Canada.[1]

Automation in the addiction treatment industry

  • 61.7% of U.S. behavioral-health treatment facilities accepted Medicaid in 2024.[2]
  • 41.7% of U.S. behavioral-health treatment facilities accepted Medicare in 2024.[2]
  • 46.6% of substance-use treatment facilities reported offering telehealth in the 2024 U.S. N-SUMHSS data.[2]
  • 25.7% of U.S. substance-use treatment facilities reported using telemedicine or telehealth in 2015.[3]
  • 13.2% of U.S. behavioral-health treatment facilities reported active participation in health-information exchanges in 2024.[2]
  • 19.1% of U.S. behavioral-health treatment facilities reported using both electronic health records and paper records in 2024.[2]

Digital Transformation in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 71% used predictive AI integrated into electronic health records in 2024.[4]
  • Among healthcare respondents to KPMG’s global technology survey, 49% were adopting DevSecOps approaches to adapt digital-transformation strategies.[5]
  • About 70% of surveyed healthcare executives said investing in technology platforms for digital tools and services would be important or very important in 2025.[6]
  • Across surveyed healthcare practitioners, 60% believed their organizations’ digital experiences met or exceeded customer needs in 2025.[7]
  • About 90% of surveyed global healthcare C-suite executives expected digital technology use to accelerate in 2025, including 50% anticipating a significant impact.[6]

Technology Adoption in the healthcare services sector (sector benchmark)

  • Across U.S. non-federal acute care hospitals, 81% enabled patient access through applications using application-programming-interface specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 99% enabled patients to view health information electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 96% enabled patients to download health information electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 70% enabled patient access through applications using HL7 FHIR specifications in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 84% enabled patients to transmit health information to a third party electronically in 2024.[4]
  • Across U.S. non-federal acute care hospitals, 92% enabled patients to securely message providers in 2024.[4]

Cloud Computing in the healthcare services sector (sector benchmark)

  • Across surveyed healthcare organizations globally, 18% had started adopting cloud services but lacked a comprehensive cloud strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 8% reported minimal cloud adoption without formal strategy or governance at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 27% reported that cloud operations were well managed and integrated into overall IT strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 15% reported that cloud adoption was fully integrated into business strategy at the end of 2025.[8]
  • Across surveyed healthcare organizations globally, 31% had a formal cloud strategy and governance framework that was not yet integrated into IT strategy at the end of 2025.[8]

Big Data in the healthcare services sector (sector benchmark)

  • Across Brazilian healthcare facilities conducting Big Data analytics, 65% used patient demographics, forms, or medical-record data in 2024.[9]
  • Across Brazilian healthcare facilities conducting Big Data analytics, 38% used geolocation data from mobile phones, wireless connections, or GPS in 2024.[9]

05 Statistics

Data & Analytics

Admissions and infrastructure data highlight operational friction: 50% of clinical data abstractors reported that data inaccuracies hamper registry efforts in 2024. Facilities show broad EHR use, with 2.7% reporting no system and no implementation plan.

Business intelligence in the addiction treatment industry

  • 50.4% of U.S. substance-use treatment admissions were referred by the client or friends and family in 2024.[3]
  • 50.7% of 27,957 U.S. substance-use and mental-health treatment facilities exclusively used electronic health records in 2024.[3]
  • 40.7% of U.S. substance-use treatment admissions received ambulatory, non-intensive outpatient services in 2024.[3]
  • 2.7% of 27,957 U.S. substance-use and mental-health treatment facilities reported no electronic health-record system and no implementation plan in 2024.[3]
  • 2.5% of 27,957 U.S. substance-use and mental-health treatment facilities planned to implement electronic health records in 2024.[3]
  • 27,957 U.S. substance-use and mental-health treatment facilities were included in the 2024 electronic-health-record question.[3]

Data analytics in the addiction treatment industry

  • Approximately one-third of Medicaid-enrolled U.S. youths with opioid use disorder engaged in care in a 2016–2023 claims-data study.[10]
  • More than 90,000 drug-overdose deaths occurred in the United States in 2020, according to a study of post-residential-treatment follow-up among Medicaid enrollees.[11]
  • 339,224 commercially insured U.S. adults were included in a longitudinal analysis of opioid-use-disorder treatment trajectories.[12]
  • 3.125% of Medicaid-enrolled U.S. youths with opioid use disorder achieved at least 180 days of medication retention in a 2016–2023 claims-data study.[10]
  • 229,847 Medicaid-enrolled U.S. adolescents and young adults with opioid use disorder were included in a 2016–2023 claims-data cohort.[10]
  • Approximately 50% of Medicaid-enrolled U.S. youths with opioid use disorder initiated treatment in a 2016–2023 claims-data study.[10]

Data Quality in the healthcare services sector (sector benchmark)

  • 50% of U.S. healthcare clinical data abstractors reported that data inaccuracies hamper clinical registry efforts in 2024.[13]
  • 75% of U.S. healthcare organizations represented in the survey predominantly used clinical registry data for quality and process improvement in 2024.[13]
  • 40% of U.S. healthcare clinical data abstractors reported that manual data entry hampers clinical registry efforts in 2024.[13]
  • 40% of U.S. healthcare clinical data abstractors reported that incomplete data hampers clinical registry efforts in 2024.[13]
  • 8% of U.S. healthcare organizations rated their provider data as excellent in 2022.[14]

Data Governance in the healthcare services sector (sector benchmark)

  • 77% of healthcare organizations reported that their governance functions met at least quarterly in 2025.[14]
  • 66% of healthcare organizations reported multidisciplinary representation in governance, including patient or consumer representatives, in 2025.[14]
  • 38% of healthcare organizations had formal data and information quality-management statements in 2025.[14]
  • 39% of healthcare organizations reported having a formally chartered data-governance function in 2025.[14]
  • 10% of healthcare organizations managed data governance exclusively within IT in 2025.[14]
  • 72% of healthcare organizations operated governance using approved policy and standards frameworks in 2025.[14]

KPIs in the addiction treatment industry

  • 7 days is the shorter continuity-of-care interval specified for Medicaid beneficiaries after medically managed withdrawal from alcohol or drugs.[15]
  • 30 days is the second follow-up interval tracked by the Medicaid adult substance-use emergency-department quality measure.[15]
  • 13.8% of U.S. substance-use treatment admissions identified other opiates and synthetics as the primary substance in 2024.[3]
  • 52 of 54 states and jurisdictions reported the adult substance-use emergency-department follow-up measure for Core Set Year 2025.[15]
  • 27.8% was the median 7-day follow-up rate for Medicaid adults aged 18–64 after an emergency-department visit for substance use in Core Set Year 2025.[15]
  • 14 days is one of the continuity-of-care intervals specified for Medicaid beneficiaries after medically managed withdrawal from alcohol or drugs.[15]

06 Statistics

Strategy & Growth

Care delivery shifts show up in telehealth and modality mix, including telehealth treatment at 3.8% for U.S. adolescents (12–17) in 2024. Demand drivers remain tied to opioid and alcohol problem reporting in England.

Growth in the addiction treatment industry

  • 63% of people starting treatment in England in 2023–2024 reported an alcohol problem.[16]
  • 138,255 adults, or 42% of those in treatment, were receiving opiate treatment in England in 2024–2025.[16]
  • 99,955 adults, or 30% of those in treatment, were receiving alcohol-only treatment in England in 2024–2025.[16]
  • 2,310 adults were in structured drug and alcohol treatment in Devon during 2023–2024.[17]
  • 23% of people starting treatment in England in 2023–2024 reported an opiate problem.[16]
  • 3,609 people started treatment for ketamine problems in England in 2023–2024, more than eight times the 426 recorded in 2014–2015.[16]

Differentiation in the addiction treatment industry

  • 3.8% of adolescents aged 12 to 17 with a substance-use disorder in the United States received treatment through telehealth in 2024.[3]
  • 3.6% of young adults aged 18 to 25 with a substance-use disorder in the United States received treatment through telehealth in 2024.[3]
  • 3% of patients in a Los Angeles County low-barrier addiction-medication service received naltrexone for alcohol-use disorder during 2020–2025.[18]
  • 91% of patients in a Los Angeles County low-barrier addiction-medication service received buprenorphine for opioid-use disorder during 2020–2025.[18]
  • 75% of patients using a Los Angeles County low-barrier addiction-medication service were male during 2020–2025.[18]
  • 5% of patients in a Los Angeles County low-barrier addiction-medication service received off-label medication for stimulant-use disorder during 2020–2025.[18]

Mergers and acquisitions in the addiction treatment industry

  • Crossroads Treatment Centers acquired Family Health Services in July 2025, adding outpatient addiction-treatment locations in New Kensington and Ford City, Pennsylvania.[19]
  • Transaction volumes in the addiction-treatment-center sector remained stable from 2024 through 2025.[20]
  • 79 addiction-treatment-provider transactions were completed in 2021.[21]
  • 29 addiction-treatment-provider transactions were announced in 2023.[21]
  • Northpoint Recovery acquired Brick House Recovery in 2026, adding three adult outpatient facilities and a virtual-treatment program.[22]
  • 36 addiction-treatment-provider transactions were announced in 2024.[21]

07 Statistics

People & Workforce

Workforce constraints stay central: annual turnover in the field is reported as up to 50% in 2026, with an estimated 23% to 33% average annual turnover among addiction counselors and supervisors. Facility staffing also appears in national survey participation.

Hiring in the addiction treatment industry

  • 63 addiction-treatment organizations participated in the 2025 National Addiction Industry Salary Survey.[23]
  • 355 addiction-treatment facilities participated in the 2025 National Addiction Industry Salary Survey.[23]
  • 256,449 paid staff members worked in U.S. specialty addiction-treatment facilities in 2016.[24]
  • 197,559 full-time-equivalent paid staff members worked in U.S. specialty addiction-treatment facilities in 2016.[24]
  • 11,089 employees were represented in the 2025 National Addiction Industry Salary Survey.[23]

Employee retention in the addiction treatment industry

  • 36% of substance-use-disorder counselors who turned over in a longitudinal study left the addiction-treatment profession completely.[11]
  • Up to 50% was the reported annual turnover rate in the substance-use-disorder treatment field in 2026.[25]
  • 23% to 33% was the estimated average annual turnover range among addiction counselors and supervisors in the United States.[26]

Remote Work in the healthcare services sector (sector benchmark)

  • Across U.S. medical groups, 18% of leaders expected their organization’s share of remote or hybrid jobs to decrease during 2024.[27]
  • Across U.S. health care and social assistance, 18% of full-time employees worked fully from home during December 2024–March 2025.[28]
  • Across U.S. medical groups, 52% reported that 1%–25% of their workforce worked remotely at least 50% of the time.[27]
  • Across U.S. medical groups, 22% of leaders expected their organization’s share of remote or hybrid jobs to increase during 2024.[27]

Hybrid Work in the healthcare services sector (sector benchmark)

  • About 12% of nonclinical healthcare administrative and customer-support jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[27]
  • About 6% of U.S. healthcare jobs were hybrid in a 2024 Robert Half survey cited by the Medical Group Management Association.[27]
  • Across U.S. health care and social assistance, 24% of full-time employees were in hybrid arrangements during December 2024–March 2025.[28]
  • Across U.S. healthcare practitioners and technical roles, 16% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[27]
  • Across U.S. healthcare support roles, 14% had part-time remote availability, equivalent to hybrid availability, in the 2022 McKinsey American Opportunity Survey.[27]

Upskilling in the addiction treatment industry

  • 13,900 U.S. substance-abuse treatment facilities required continuing education for staff in 2013.[3]
  • 10,391 U.S. substance-abuse treatment facilities used case review by an appointed quality-review committee in 2013.[3]
  • 73% of U.S. substance-abuse treatment facilities used case review by an appointed quality-review committee in 2013.[3]
  • 98% of U.S. substance-abuse treatment facilities required continuing education for staff in 2013.[3]
  • 95% of U.S. substance-abuse treatment facilities conducted regularly scheduled case reviews with supervisors in 2013.[3]

Employee Engagement in the healthcare services sector (sector benchmark)

  • Across NHS staff, the national staff-engagement theme score was 6.64 in the second quarter of 2024/25.[29]
  • Across U.S. healthcare workers, 78% believed their organization cared about their safety in 2024.[30]
  • Among U.S. healthcare advanced practice providers, 52% felt heard in 2024.[30]
  • U.S. registered nurses with low teamwork scores were 1.53 times more likely to leave their healthcare organization in 2024.[30]
  • Across 2.3 million U.S. healthcare workers, employee engagement declined by 0.02 points in 2024.[30]

DEI in the addiction treatment industry

  • 21% of paid staff in U.S. specialty addiction-treatment facilities were medical staff in 2016.[24]
  • 40% of paid staff in U.S. specialty addiction-treatment facilities were counselors in 2016.[24]
  • 16% of paid staff in U.S. specialty addiction-treatment facilities were administrative staff in 2016.[24]

08 Statistics

Customer & Sales

Referral and conversion dynamics remain measurable: 50.4% of 2024 admissions were referred by the individual, friends, or family, and 24.6% came through criminal-justice or DUI referrals. Marketing-to-admission funnels are also quantified in Webserv datasets.

Customer experience in the addiction treatment industry

  • 87% of Los Angeles County adult substance-use treatment clients said they received needed services in 2022.[31]
  • 95.2% of Ashley Treatment patients said they would recommend the organization to a friend or family member with substance-use disorder in 2024.[32]
  • 93% of Los Angeles County adult substance-use treatment clients said they felt welcomed in 2022.[31]
  • 91% of Los Angeles County adult substance-use treatment clients said they would recommend services to others in 2022.[31]

Customer retention in the addiction treatment industry

  • 60% treatment retention was reported in a U.S. study of 177,115 people with substance-use disorder over four years.[11]
  • 30% of clients at one U.S. specialty addiction-treatment provider withdrew or were removed within 30 days of entering treatment.[11]
  • 40.3% of Mexican outpatient substance-use treatment patients completed a 12-week program in a study of 161 patients.[11]
  • 38% of U.S. outpatient substance-use treatment patients remained engaged at the 45-to-75-day follow-up in a study of 1,857 patients.[11]

Customer acquisition in the addiction treatment industry

  • 9.4% of U.S. substance-use treatment admissions in 2024 were referred by a substance-use care provider.[3]
  • 24.6% of U.S. substance-use treatment admissions in 2024 came through criminal-justice or DUI referrals.[3]
  • 0.4% of U.S. substance-use treatment admissions in 2024 were referred by a school or educational institution.[3]
  • 7.8% of U.S. substance-use treatment admissions in 2024 came from other community referrals.[3]
  • 50.4% of U.S. substance-use treatment admissions in 2024 were referred by the individual, friends, or family.[3]

Lead generation in the addiction treatment industry

  • 35.9% was the default viable-verification-to-admission conversion rate in Webserv’s 2025 rehabilitation-treatment dataset.[33]
  • 14.6% was the search-engine lead close rate reported for rehabilitation centers in a 2025 channel-comparison analysis.[34]
  • 42.8% was the default verification-of-benefits-to-viable-verification conversion rate in Webserv’s 2025 rehabilitation-treatment dataset.[33]
  • $406 was the average cost per lead across Webserv-managed rehabilitation-treatment campaigns in 2025.[33]
  • 15.9% was the default lead-to-verification-of-benefits conversion rate in Webserv’s 2025 rehabilitation-treatment dataset.[33]

09 Statistics

Marketing & Brand

Digital acquisition costs are quantified in rehabilitation marketing benchmarks, including $16,608 average cost per admission in 2025. Social signals show engagement variation in outpatient addiction treatment, with 69.0% saying they would join an online support group.

Marketing in the addiction treatment industry

  • 65 search-engine-optimization clients were included in Webserv’s 2024 rehabilitation-treatment marketing benchmark.[33]
  • $16,608 was the average cost per admission in Webserv’s 2025 rehabilitation-treatment marketing dataset.[33]
  • Under $8,000 was the cost per admission for top-performing campaigns in Webserv’s 2025 rehabilitation-treatment benchmark.[33]
  • $7.5 million in managed rehabilitation advertising spend supported Webserv’s 2024 marketing benchmark report.[33]
  • $16.5 million in managed rehabilitation advertising spend formed Webserv’s 2025 marketing benchmark dataset across more than 50 treatment centers.[33]

Digital marketing in the addiction treatment industry

  • $16.5 million in behavioral-health advertising spend underpinned Webserv’s 2025 paid-media calculator for treatment providers.[33]
  • 104 admissions in one month were attributed to digital marketing in a treatment-center case study.[35]
  • $2,552 was the average cost per verification of benefits in Webserv’s 2025 rehabilitation-treatment digital-marketing dataset.[33]
  • 50+ treatment centers contributed to Webserv’s 2025 digital-marketing benchmark dataset.[33]
  • 1.87x was the average lifetime-value-to-customer-acquisition-cost ratio shown in Webserv’s 2025 rehabilitation-treatment acquisition calculator.[33]

Social media in the addiction treatment industry

  • 69.0% of respondents in outpatient addiction treatment said they would join an online support group.[36]
  • 59.7% of respondents in outpatient addiction treatment had not posted about their personal recovery on social-media accounts.[36]
  • 47.4% of respondents with social-media accounts in outpatient addiction treatment had seen recovery information at least sometimes.[36]
  • 62% of people with substance-use disorder surveyed in treatment in 2025 said they reduced or stopped social-media use during treatment.[37]
  • 62.3% of respondents in outpatient addiction treatment said they would join a Facebook support group.[36]

Influencer Marketing in the healthcare services sector (sector benchmark)

  • 38% of posts from U.S.-focused health and wellness influencers promoted a product, service or subscription in 2026.[38]
  • 92% of U.S.-focused health and wellness influencers included product or service promotions at least occasionally in 2026.[38]
  • 50% of healthcare and pharmaceutical marketers reported dedicated, growing creator/influencer budgets in 2026, compared with 58% globally.[39]
  • 33% of U.S.-focused health and wellness influencers promoted a product, service or subscription in more than half of their posts in 2026.[38]
  • 50% of U.S. physicians surveyed had changed prescribing choices based on healthcare influencer or KOL content on social media in 2024.[40]

10 Statistics

Operations & Execution

Operational capability varies across service types: inpatient utilization is high, with a 91.2% utilization rate for designated hospital-inpatient beds in 2024. Many facilities report assessment and pre-treatment services, at 99.4%.

Process optimization in the addiction treatment industry

  • 84.7% of U.S. substance-use treatment facilities offered mental-disorder screening in 2024.[3]
  • 405 hours of care were provided per 100 outpatient clients per week by U.S. facilities treating both substance-use and mental-health conditions.[41]
  • 10% longer treatment stays were associated with 7% higher episode costs in a U.S. sample of 67 outpatient drug-free programs.[11]
  • 99.4% of U.S. substance-use treatment facilities offered assessment and pre-treatment services in 2024.[3]
  • 193 hours of care were provided per 100 outpatient clients per week by facilities focused on substance-use-disorder treatment in the United States.[41]

Operational efficiency in the addiction treatment industry

  • 91.2% was the 2024 utilization rate for designated hospital-inpatient substance-use-treatment beds in the United States.[3]
  • 30 designated hospital-inpatient beds was the average per U.S. facility in 2024.[3]
  • 85.1% was the 2024 utilization rate for designated residential substance-use-treatment beds in the United States.[3]
  • 32 designated residential beds was the average per U.S. facility in 2024.[3]
  • 246 days was the mean stay for outpatient medication-assisted treatment for opioid-use disorder among New Jersey clients completing treatment in 2023.[42]

Quality management in the addiction treatment industry

  • 81.2% of addiction-treatment organizations reported having a staff member monitoring licensing, payer-contract, and accreditation requirements in the survey period.[11]
  • 95.8% of U.S. substance-use treatment facilities reported licensing, certification, or accreditation in 2024.[3]
  • 99.4% of U.S. opioid-treatment-program facilities reported licensing, certification, or accreditation in 2025.[3]
  • 25.9% of U.S. substance-use treatment facilities reported Joint Commission accreditation in 2024.[3]
  • 33.9% of U.S. substance-use treatment facilities reported CARF accreditation in 2024.[3]

Supply chain in the addiction treatment industry

  • 2,093 U.S. outpatient facilities with opioid-treatment programs were included in the 2025 N-SUMHSS detailed-table total.[3]
  • 58.8% of U.S. opioid-treatment-program facilities reported state health-department licensing or certification in 2025.[3]
  • 2,320 U.S. facilities with opioid-treatment programs were included in the 2025 N-SUMHSS detailed-table total.[3]
  • 77.5% of U.S. outpatient opioid-treatment-program facilities reported Drug Enforcement Administration authorization or oversight in 2025.[3]
  • 63.1% of U.S. outpatient opioid-treatment-program facilities reported CARF accreditation in 2025.[3]

Outsourcing / Offshoring in the healthcare services sector (sector benchmark)

  • 46% of global healthcare providers used third-party providers for customer-experience services in 2024, based on a survey of 28 healthcare-provider executives.[43]
  • 20% of U.S. medical-group leaders planned to outsource or automate some revenue-cycle-management activities in 2024, according to an MGMA poll with 262 responses.[27]
  • 54% of global healthcare providers used third-party providers for supply-chain services in 2024, based on a survey of 28 healthcare-provider executives.[43]
  • 18% of U.S. medical-group leaders planned to outsource or automate patient communications in contact centers in 2024, according to an MGMA poll with 262 responses.[27]
  • 43% of global healthcare providers used third-party providers for payroll services in 2024, based on a survey of 28 healthcare-provider executives.[43]

11 Statistics

Finance & Pricing

Medicare bundle rates for 2026 set pricing anchors for opioid-treatment-program reimbursement, including $296.57 per weekly oral-buprenorphine bundle. Historical residential cost metrics provide additional benchmarks for cost comparisons.

Pricing strategy in the addiction treatment industry

  • $357 was the average daily residential addiction-treatment cost at nonprofit U.S. programs in 2019.[44]
  • $5,712 was the average upfront payment requested by nonprofit U.S. residential addiction-treatment programs in 2019.[44]
  • 74% of U.S. residential addiction-treatment programs required some upfront payment in 2019.[44]
  • 50% of U.S. nonprofit residential addiction-treatment programs required some upfront payment in 2019.[44]
  • $618 was the average daily residential addiction-treatment cost in the United States in 2019.[44]

Cost reduction in the addiction treatment industry

  • $1,853 was the average client cost per outpatient methadone treatment episode in a U.S. cost study.[11]
  • $296 was the average cost per residential-rehabilitation bed-day reported in an Australian NGO alcohol-and-other-drug treatment cost study.[45]
  • $571 was the average client cost per outpatient non-methadone treatment episode in a U.S. cost study.[11]
  • $19 was the average client cost per visit for outpatient methadone treatment in a U.S. cost study.[11]

Profitability in the addiction treatment industry

  • 6,724 private for-profit substance-use treatment facilities operated in the United States in 2024.[3]
  • 88% of for-profit U.S. residential addiction-treatment programs required upfront payment in 2019, compared with 50% of nonprofit programs.[44]
  • $758 was the average daily residential-treatment cost at for-profit U.S. addiction-treatment programs in 2019, versus $357 at nonprofit programs.[44]
  • 7,697 private nonprofit substance-use treatment facilities operated in the United States in 2024.[3]

Financial planning in the addiction treatment industry

  • $758 was the average daily residential addiction-treatment cost among U.S. for-profit programs in 2019.[44]
  • 74% of U.S. residential addiction-treatment programs required upfront payment in 2019.[44]
  • $357 was the average daily residential addiction-treatment cost among U.S. nonprofit programs in 2019.[44]
  • $618 was the average daily residential addiction-treatment cost among U.S. programs in 2019.[44]
  • 50% of nonprofit U.S. residential addiction-treatment programs required upfront payment in 2019.[44]

12 Statistics

Product & Service

Medication and digital therapeutics show measurable retention and module completion: digital-therapeutic participants retained in treatment at 76.2% versus 63.2% for treatment as usual. Fewer than 15% of commercially insured patients initiated medication for opioid use disorder within three months of diagnosis.

Product development in the addiction treatment industry

  • 76.2% of digital-therapeutic participants were retained in treatment, compared with 63.2% receiving treatment as usual.[46]
  • 3 FDA-approved medications are available for opioid use disorder in the United States: buprenorphine, methadone and naltrexone, as of 2026.[47]
  • 52% of real-world users of a prescription digital therapeutic completed all core treatment modules in a geographically diverse United States sample.[46]
  • 399 patients with substance use disorders participated in a clinical analysis of a prescription digital therapeutic in the United States.[46]
  • 50.6% of primary-care patients activated a prescription digital therapeutic for substance use disorder in a real-world engagement study.[46]

Product lifecycle in the addiction treatment industry

  • 27.5% was the median 180-day retention rate among Medicaid patients at U.S. opioid treatment programs.[37]
  • 41.5% was the median 90-day retention rate among Medicaid patients at U.S. opioid treatment programs.[37]
  • 19 of 77 medication-treatment studies reported outcomes beyond one year in a 2014–2024 review of opioid-use-disorder treatment.[48]
  • 37 of 77 medication-treatment studies reported retention at one year or longer, according to a 2014–2024 review of opioid-use-disorder treatment.[48]
  • Fewer than 15% of commercially insured U.S. patients initiated medication for opioid use disorder within three months of diagnosis.[12]

After-sales in the addiction treatment industry

  • 30.77% of 91 Arizona substance-use-disorder treatment providers reported offering virtual check-ins after treatment in 2023.[49]
  • 43.96% of 91 Arizona substance-use-disorder treatment providers reported linking clients to community self-help groups after treatment in 2023.[49]
  • 26.37% of 91 Arizona substance-use-disorder treatment providers reported offering structured cognitive-behavioral aftercare in 2023.[49]
  • 22.8% of Medicaid enrollees with a substance-use-disorder inpatient admission received outpatient follow-up within 14 days across 10 U.S. states.[11]
  • 20.88% of 91 Arizona substance-use-disorder treatment providers reported monitoring clients with drug testing after treatment in 2023.[49]

Value proposition in the addiction treatment industry

  • 45.8% of patients completed the user guide after activating a prescription digital therapeutic in primary care.[46]
  • 11% was the approximate increase in odds of abstinence during weeks 9–12 associated with each additional digital-therapeutic module completed by study completers.[46]
  • 38.6% of primary-care patients using a prescription digital therapeutic completed at least one treatment module.[46]
  • 4 was the median number of modules completed by primary-care patients who used a prescription digital therapeutic for substance use disorder.[46]
  • 13.3% of primary-care patients using a prescription digital therapeutic met the vendor-defined treatment-completion criterion.[46]

13 Statistics

Sustainability & Ethics

Need vs. treatment access remains a sustainability stressor, with 50 million Americans meeting substance use disorder criteria in 2023 and 1 in 4 receiving treatment. State reform activity in New Jersey is tied to corruption and fraud findings.

Sustainability in the addiction treatment industry

  • 50 million Americans met criteria for a substance use disorder in 2023, underscoring the treatment industry’s unmet service-sustainability challenge in the United States.[50]
  • 17% of Americans met criteria for a substance use disorder in 2023, according to an addiction-treatment financial-sustainability policy statement.[50]
  • 1 in 4 Americans who met criteria for a substance use disorder received treatment in 2023, indicating substantial unmet demand for sustainable addiction-treatment capacity.[50]

Ethics in the addiction treatment industry

  • 2 of the 7 New Jersey addiction-treatment reform bills had been approved by the Assembly by September 2024, according to the State Commission of Investigation.[42]
  • 7 reform bills were introduced in New Jersey in February 2024 after an investigation found corruption, fraud and unethical conduct across the addiction-rehabilitation industry.[42]

15 Statistics

Globalization & Expansion

International coverage varies by region, with 26% of people with drug use disorders receiving treatment in Europe in 2022 and 5.1% receiving treatment in Asia in 2022. In the United States, telehealth reach is quantified at 3.6 million people in 2024.

Globalization in the addiction treatment industry

  • 26% of people with drug use disorders received treatment in Europe in 2022.[58]
  • About 1 in 18 women with drug use disorders received treatment globally in 2022.[58]
  • 5.1% of people with drug use disorders received treatment in Asia in 2022.[58]
  • Treatment-contact coverage ranged from less than 1% to no more than 35% across countries reporting data for 2019.[59]
  • About 1 in 7 men with drug use disorders received treatment globally in 2022.[58]

Cultural adaptation in the addiction treatment industry

  • Women represented 2.8% of people receiving drug-related treatment in Asia in 2022.[58]
  • Women represented 22% of people receiving drug-related treatment globally in 2022.[58]
  • 68.2% of adults in treatment in England were men and 31.8% were women in 2024–2025.[16]
  • Women represented 6% of people receiving treatment for new psychoactive-substance-related disorders in 2022.[58]
  • Women represented 27% of people receiving treatment for amphetamine-related disorders in 2022.[58]

Stakeholder management in the addiction treatment industry

  • 78% of patients obtained medication after prescriptions from a Los Angeles County addiction-medication consultation service during 2020–2025.[18]
  • 21% of patients who obtained prescriptions through a Los Angeles County addiction-medication service were scheduled for follow-up care during 2020–2025.[18]
  • 47% of calls to a Los Angeles County low-barrier addiction-medication service came from harm-reduction syringe-services-program staff during 2020–2025.[18]
  • 19% of calls to a Los Angeles County low-barrier addiction-medication service came from outpatient programs during 2020–2025.[18]
  • 19% of calls to a Los Angeles County low-barrier addiction-medication service came from correctional-health re-entry coordinators during 2020–2025.[18]

Distribution channels in the addiction treatment industry

  • 0.9% of people aged 12 or older in the United States received inpatient substance-use treatment in 2024, equal to 2.6 million people.[3]
  • 1.3% of people aged 12 or older in the United States received substance-use treatment via telehealth in 2024, equal to 3.6 million people.[3]
  • 0.5% of people aged 12 or older in the United States received medication for alcohol-use disorder in 2024, equal to 1.3 million people.[3]
  • 0.7% of people aged 12 or older in the United States received medication for opioid-use disorder in 2024, equal to 2.2 million people.[3]
  • 52,401 adults received alcohol and drug treatment in prisons and secure settings in England between April 2024 and March 2025.[16]

Key questions about the Addiction Treatment Industry

How big is the U.S. addiction treatment demand vs. capacity?
The U.S. addiction treatment industry served 7.6 million people in 2025, while 47.2 million needed treatment. Received treatment in 2025 was 7.6M; needed treatment in 2025 was 47.2M.
What is the scale of the facility supply?
The 2025 N-SUMHSS counted 15,472 substance-use treatment facilities across the United States and territories. Private for-profit providers accounted for 6,441 facilities (about 41.6%).
Which companies lead the addiction treatment industry?
Camurus leads Gitnux's 2026 addiction treatment ranking with an Overall score of 9.1, with licenses Brixadi, long-acting buprenorphine treatment. Universal Health Services is the highest-ranked care provider at 9.0, with 346 inpatient behavioral health facilities and 168 outpatient facilities in 2025.
Where has technology adoption shown measurable traction in the industry?
In 2024 N-SUMHSS-based data, 46.6% of substance-use treatment facilities reported offering telehealth. The 2025 federal demand data also shows 3.6 million people receiving telehealth.
How fragmented is the market structure by facility count?
The 2025 N-SUMHSS identified 15,472 facilities including 6,441 private for-profit and 4,740 private nonprofit facilities. The federal facility survey does not publish a national revenue-based concentration ratio for commercial operators.
How do Medicare payment rates affect opioid-treatment-program pricing?
For calendar year 2026, CMS set national Medicare payment rates for opioid-treatment-program bundles at $277.29 per weekly methadone bundle, $296.57 per weekly oral-buprenorphine bundle, and $2,063.77 per monthly injectable-buprenorphine bundle. These are national rates before locality adjustments.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Kevin O'Brien. (2026, February 13). Addiction Treatment Industry Statistics. Gitnux. https://gitnux.org/addiction-treatment-industry-statistics
MLA
Kevin O'Brien. "Addiction Treatment Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/addiction-treatment-industry-statistics.
Chicago
Kevin O'Brien. 2026. "Addiction Treatment Industry Statistics." Gitnux. https://gitnux.org/addiction-treatment-industry-statistics.

Sources & references

70 sources cited across this report

  1. psychiatry.org
  2. nature.com
  3. samhsa.gov
  4. healthit.gov
  5. kpmg.com
  6. deloitte.com
  7. business.adobe.com
  8. go.rackspace.com
  9. cetic.br
  10. jamanetwork.com
  11. pmc.ncbi.nlm.nih.gov
  12. sciencedirect.com
  13. carta.healthcare
  14. intersystems.com
  15. medicaid.gov
  16. gov.uk
  17. devon.gov.uk
  18. nacchoapplication.secure-platform.com
  19. crossroadstreatmentcenters.com
  20. stout.com
  21. mertztaggart.com
  22. northpointholdings.com
  23. naatp.org
  24. s3.amazonaws.com
  25. frontiersin.org
  26. ncbi.nlm.nih.gov
  27. mgma.com
  28. wfhresearch.com
  29. england.nhs.uk
  30. pressganey.com
  31. publichealth.lacounty.gov
  32. ashleytreatment.org
  33. webserv.io
  34. rehab.com
  35. premazon.com
  36. jmir.org
  37. doi.org
  38. pewresearch.org
  39. brand-news.it
  40. sermo.com
  41. aspe.hhs.gov
  42. nj.gov
  43. tcs.com
  44. healthaffairs.org
  45. nada.org.au
  46. pubmed.ncbi.nlm.nih.gov
  47. fda.gov
  48. deriu82xba14l.cloudfront.net
  49. azdhs.gov
  50. downloads.asam.org
  51. ache.org
  52. ponemonsullivanreport.com
  53. proofpoint.com
  54. kff.org
  55. hfmmagazine.com
  56. sophos.com
  57. sec.gov
  58. unodc.org
  59. who.int
  60. cms.gov
  61. cdc.gov
  62. camurus.com
  63. ir.uhs.com
  64. baymark.com
  65. bhgrecovery.com
  66. investor.alkermes.com
  67. discoverybehavioralhealth.com
  68. summitbhc.com
  69. americanaddictioncenters.org
  70. bhw.hrsa.gov